uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting – GlobeNewswire

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 28, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that five data presentations, of which two are oral presentations, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting being held May 11-14.

"Our presentations at ASGCT showcase our gene therapy expertise in hemophilia and Huntingtons disease, as well as advantages of the AAV5 vector in dosing through pre-existing neutralizing antibodies, stated Ricardo Dolmetsch, Ph.D.president of research and development at uniQure. In addition, we look forward to presenting preclinical data demonstrating the potential of the miQURE technology used in our CNS product candidates to be effective in liver-based diseases as well.

Specific details on uniQures presentations at ASGCT include:

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.www.uniQure.com

uniQure Contacts:

See the original post here:
uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - GlobeNewswire